Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4300 A retrospective comparison of preoperative characteristics and surgical outcomes in small intestine neuroendocrine neoplasms (SiNENs) and small intestine adenocarcinoma

Introduction: SiNENs are complex tumours with unique behaviour. Despite 30 years of progress, limited data and diagnostic challenges hinder understanding, complicating assessment of their biology and outcomes.

Conference:

Presenting Author: Zamparas A

Authors: Herzog T, Zamparas A, Uhl W, Strotmann J, Höhn P,

Keywords: small intestine NEN, small bowel adenocarcinoma, NET, Chromogranin A, 5-year follow-up, 10-year follow-up,

#3954 Comparison of transarterial embolisation (TAE) or chemoembolisation (TACE) using streptozotocin (STZ) and biomarker study in patients with metastatic neuroendocrine tumors (NET)

Introduction: We compared TACE and TAE in patients with pancreatic (pNET) or small-intestine NET (siNET) and explored the role of biomarkers related to alkylating agents (O6-methylguanine-methyltransferase [MGMT], alkylpurine–DNA–N-glycosylase [APNG]) or hypoxia (Carbonic anhydrase IX [CAIX]).

Conference:

Presenting Author: de Mestier L

Authors: Vedie A, Dioguardii Burgioo M, Matteini F, Akez M, Hentic O,

Keywords: transarterial embolization, chemoembolization, metastatic neuroendocrine tumor, biomarker,

#48 Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma

Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Druce M, Maher K, Grozinsky-Glasberg S, Gross D, Chambers J,

Keywords: medullary thyroid cancer, calcitonin, everolimus, RAD001,